Bio-Tissue Revenue and Competitors

Miami, FL USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Bio-Tissue's estimated annual revenue is currently $62.9M per year.(i)
  • Bio-Tissue's estimated revenue per employee is $155,000

Employee Data

  • Bio-Tissue has 406 Employees.(i)
  • Bio-Tissue grew their employee count by 39% last year.

Bio-Tissue's People

NameTitleEmail/Phone
1
Chief Scientific Officer/FounderReveal Email/Phone
2
CFOReveal Email/Phone
3
CIOReveal Email/Phone
4
General Counsel and Chief Compliance OfficerReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
VP MarketingReveal Email/Phone
7
VP IT and Operational ExcellenceReveal Email/Phone
8
VP Regulatory AffairsReveal Email/Phone
9
VP Human ResourcesReveal Email/Phone
10
VP OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15.3M995%N/AN/A
#2
$1.1M7-30%N/AN/A
#3
$3.7M244%N/AN/A
#4
$4.3M28-3%N/AN/A
#5
$2.5M16N/AN/AN/A
#6
$0.8M50%N/AN/A
#7
$1.1M70%N/AN/A
#8
$2.5M167%N/AN/A
#9
$1.4M9-25%N/AN/A
#10
$0.6M40%N/AN/A
Add Company

What Is Bio-Tissue?

Bio-Tissue (www.biotissue.com), a business unit of TissueTech, Inc., develops and markets regenerative therapies that allow eye care professionals to advance the standard of care for treating the ocular surface. Its core products include cryopreserved amniotic membrane and umbilical cord-based tissue with innate therapeutic actions scientifically proven to heal the ocular surface. The Company’s proprietary CryoTek® preservation method ensures the tissue retains its biologic activity and healing components. To date, more than 300,000 allografts have been transplanted collectively by Bio-Tissue and sister company Amniox Medical (TissueTech business units).

keywords:N/A

N/A

Total Funding

406

Number of Employees

$62.9M

Revenue (est)

39%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Bio-Tissue News

2022-04-13 - Satellite Bio launches with $110M to develop injectable tissues

Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapies · Amgen opts to DARP-out after seeing early data from...

2022-04-13 - Satellite Bio Reveals Pioneering Tissue Therapeutics ...

Satellite Bio reveals pioneering Tissue Therapeutics, bioengineered tissues that restore organ function, bringing hope across diseases. Tweet...

2022-04-13 - Satellite Bio launches with new approach to bioengineering ...

The company aims to translate the work of Bhatia, Chen and their cofounder Arnav Chhabra into “tissue therapeutics” — regenerative medicines...

2021-03-01 - TissueTech Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug TTBT01

MIAMI, March 1, 2021 /PRNewswire/ -- Bio-Tissue, Inc., a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M40875%N/A
#2
$102.9M410N/AN/A
#3
$109.3M41010%$12M
#4
N/A4117%N/A
#5
$35M414-6%N/A